TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2754149

Group type: COMPARATOR
Intervention: Metaproterenol sulfate aerosol (MPA) inhalation and placebo injection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epinephrine injection (EPI) and inhaled placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Crossover comparison regimen after initial treatment
Number of subjects: 100
Study: 1278718

Group type: EXPERIMENTAL
Intervention: Diazepam plus hyoscine butylbromide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (secretin and cholecystokinin without drugs)
Number of subjects: 10
Study: 31863497

Group type: EXPERIMENTAL
Intervention: Mentors with higher levels of depressive symptoms
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Mentors who experienced higher levels of early life stress
Number of subjects: 340
Study: 31174256

Group type: EXPERIMENTAL
Intervention: PM2.5 exposed group
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study: 28383476

Group type: EXPERIMENTAL
Intervention: Prehospital transfusion (PHT) of plasma and/or RBCs
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Crystalloid resuscitation (Control)
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Prehospital transfusion (PHT)
Number of subjects: 1058
Study: 26491119

Group type: EXPERIMENTAL
Intervention: Casein (CAS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whey protein (WHE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: α-lactalbumin-enriched whey protein (LAC)
Number of subjects: 10
Study: 24040949

Group type: EXPERIMENTAL
Intervention: MMA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MMA-Drep
Number of subjects: 27
Study: 21790503

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18803564

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 0
Study: 16699361

Group type: EXPERIMENTAL
Intervention: Recruitment strategies (newspaper advertisements, flyers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retention strategies (flexible scheduling, frequent contact, caring environment)
Number of subjects: 0
Study: 15566078

Group type: EXPERIMENTAL
Intervention: Vitamin K
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Multiparameter classification process
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: OC/PYD, vitamin K/PYD, vitamin K/bAP profiles
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PYD and DPD
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Other biochemical markers (AP, bAP, OC, ucOC, PICP, NTX, BSP)
Number of subjects: 29
Study: 12396862

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Dysport)
Number of subjects: 18
Study: 9564199

Group type: EXPERIMENTAL
Intervention: Adderall 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adderall 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adderall 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adderall 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ritalin (active control)
Number of subjects: 0
Study: 7811206

Group type: EXPERIMENTAL
Intervention: 10% maleic acid etched for 15 seconds (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10% maleic acid etched for 30 seconds (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid etched for 15 seconds (Group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10% maleic acid etched for 15 seconds on primary teeth (Group 4)
Number of subjects: 80
Study: 2841841

Group type: EXPERIMENTAL
Intervention: 20 g soy polysaccharide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 g soy polysaccharide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 g soy polysaccharide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid-formula diet without soy polysaccharide
Number of subjects: 0
Study: 29398452

Group type: EXPERIMENTAL
Intervention: Model and verbal instructions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Model only
Number of subjects: 30
Study: 29782181

Group type: EXPERIMENTAL
Intervention: Osteopathic abdominal manual intervention (AMI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 62
Study: 27644566

Group type: EXPERIMENTAL
Intervention: High-fat meals (HF group)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 500-kcal low-calorie density (CD) high-protein meal (HF group)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Normal meals (normal group)
Number of subjects: 232
Study: 24503114

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: simvastatin 20 mg
Number of subjects: 25
Study: 22525956

Group type: EXPERIMENTAL
Intervention: Molindone, Olanzapine, Risperidone
Number of subjects: 116
Study: 19957683

Group type: EXPERIMENTAL
Intervention: WFG-LASIK
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional LASIK
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: LASIK (both groups)
Number of subjects: 102
Study: 17986035

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 0.20% bupivacaine
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 0.20% levobupivacaine
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 0.2% solutions
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 0.25% solutions
Number of subjects: 141

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 141
Study: 15659490

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with cyclophosphamide, mitoxantrone, and etoposide followed by peripheral-blood stem-cell transplantation, repeated after 6 weeks.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard combination therapy with doxorubicin and paclitaxel (AT).
Number of subjects: 93
Study: 11843986

Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention Training (PSI) for 20 nurses over 6 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Waiting list control group (C)
Number of subjects: 33
Study: 10194129

Group type: COMPARATOR
Intervention: T cell receptor (TCR) variable (V) region expression assessment using monoclonal antibodies specific for different V region families (alpha or beta) in combination with anti‐CD4 or anti‐CD8.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Expanded T cell subsets in MM patients (N=3) with larger percentages (34-84%) of these subsets within their blood T (CD3+) cells.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Assessment of T cell repertoire in newly diagnosed, untreated MM patients (N=13).
Number of subjects: 37
Study: 7749881

Group type: EXPERIMENTAL
Intervention: Atorvastatin 2.5 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 2135210

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms) + Fenoterol (400 micrograms)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms) + Fenoterol (200 micrograms or more)
Number of subjects: 48
Study: 380736

Group type: EXPERIMENTAL
Intervention: 500 mg metronidazole as an intravenous infusion during the operation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study: 6760867

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 10
Study: 30771560

Group type: EXPERIMENTAL
Intervention: Increase standing intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Heart healthy attention-comparison condition
Number of subjects: 250
Study: 29101708

Group type: EXPERIMENTAL
Intervention: PBMT with dose of 15 J per site
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PBMT with doses of 30 J per site
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PBMT with doses of 60 J per site
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 24446755

Group type: EXPERIMENTAL
Intervention: 20 sessions of NB‐UVB treatment before transplantation
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: 30 sessions of NB‐UVB treatment after transplantation
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: 20 sessions of NB‐UVB treatment before transplantation and 30 sessions after transplantation
Number of subjects: 437

Group type: COMPARATOR
Intervention: Only transplantation (no NB‐UVB treatment)
Number of subjects: 437
Study: 22055478

Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with L-glutamine (30 g) for 2 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enteral nutrition with calcium caseinate (30 g) for 2 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with L-glutamine (30 g) followed by calcium caseinate (30 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enteral nutrition with calcium caseinate (30 g) followed by L-glutamine (30 g)
Number of subjects: 30
Study: 19345944

Group type: EXPERIMENTAL
Intervention: 200 mg of oral mifepristone followed 48 hours later with 400 microg of oral misoprostol, administered either at home or at the clinic
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Home administration of misoprostol
Number of subjects: 400
Study: 17848325

Group type: COMPARATOR
Intervention: Hysteroscopic resection with a 26F resectoscope with unipolar knife (group A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Small-diameter hysteroscopy with Versapoint device (group B)
Number of subjects: 160
Study: 15482522

Group type: EXPERIMENTAL
Intervention: Steam-cooked kiwifruit (100 degrees C for 5 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Homogenised kiwifruit preparation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fresh kiwifruit
Number of subjects: 20
Study: 11864944

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g administered every 12 hours
Number of subjects: 0
Study: 10732308

Group type: EXPERIMENTAL
Intervention: SGA infants
Number of subjects: 317

Group type: COMPARATOR
Intervention: AGA infants
Number of subjects: 317
Study: 8657964

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (1 g i.v.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rectal metronidazole (1 g suppository)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (gentamycin 80 mg i.v. + metronidazole 1 g i.v. or suppository)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postoperative observation
Number of subjects: 100
Study: 2158192

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus extract, administered orally for 1 month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus extract, administered intraperitoneally (i.p.)
Number of subjects: 0
Study: 6451235

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg daily)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nicotinamide (500 mg twice daily)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 2
Study: 29889599

Group type: EXPERIMENTAL
Intervention: MT plus TPE based on a biobehavioral approach and therapeutic exercise (Exp2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: MT plus TPE based on a biobehavioral approach (Exp1)
Number of subjects: 47

Group type: COMPARATOR
Intervention: MT (control group)
Number of subjects: 47
Study: 30819520

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (120 mg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intravenous hydromorphone (1 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (120 mg) in patients with nephrolithiasis
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intravenous hydromorphone (1 mg) in patients with nephrolithiasis
Number of subjects: 154
Study: 28724183

Group type: EXPERIMENTAL
Intervention: Myo-Inositol-based supplement (Folandrol®, Exeltis, Hungary) for two months and semen incubation with 2 mg/ml of Myo-Inositol for 2 hours before PICSI procedures.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment during the same time range).
Number of subjects: 0
Study: 24899241

Group type: EXPERIMENTAL
Intervention: Virtual reality distraction
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no virtual reality distraction)
Number of subjects: 98
Study: 23662639

Group type: EXPERIMENTAL
Intervention: Artificial intelligent virtual reality (VR)‐based vocational problem‐solving skill training programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional psycho‐educational approach
Number of subjects: 40
Study: 21195257

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 24
Study: 19943918

Group type: EXPERIMENTAL
Intervention: Best supportive nutritional care (BSNC) plus parenteral nutrition (PN)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Best supportive nutritional care (BSNC)
Number of subjects: 120
Study: 17299067

Group type: EXPERIMENTAL
Intervention: l-T(4) (1.3 microg/kg daily) for 24 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study: 14722177

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (CLMA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (PLMA)
Number of subjects: 76
Study: 12370553

Group type: COMPARATOR
Intervention: Hospital-based exercise training (Hosp)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (Home)
Number of subjects: 242
Study: 10435233

Group type: EXPERIMENTAL
Intervention: Worksite cancer control intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study: 7752912

Group type: EXPERIMENTAL
Intervention: 75-g fructose solution with 300 mg caffeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 75-g glucose solution with 300 mg caffeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: 75-g fructose solution without caffeine (placebo)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 75-g glucose solution without caffeine (placebo)
Number of subjects: 16
Study: 2306439

Group type: EXPERIMENTAL
Intervention: Topical aqueous indomethacin one hour beforehand
Number of subjects: 114

Group type: COMPARATOR
Intervention: No treatment (comparison group)
Number of subjects: 114
Study: 7002355

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg four times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (200 mg four times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin plus Sulfinpyrazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29393162

Group type: EXPERIMENTAL
Intervention: Cervitec Plus®
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 32
Study: 26324180

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) for 16 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (9 matched subjects, BMI = 34 kg/m²)
Number of subjects: 11
Study: 24811386

Group type: EXPERIMENTAL
Intervention: Resting-state fMRI data analysis
Number of subjects: 1147
Study: 22314425

Group type: EXPERIMENTAL
Intervention: GS-5885 1 mg QD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GS-5885 3 mg QD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GS-5885 10 mg QD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GS-5885 30 mg QD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GS-5885 90 mg QD
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20358265

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing‐Single Session (MI‐Single)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing‐Group (MI‐Group)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Nurse‐Led Hepatitis Health Promotion (HHP)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 256
Study: 18379010

Group type: EXPERIMENTAL
Intervention: Four-color flow cytometry
Number of subjects: 98

Group type: COMPARATOR
Intervention: Polymerase chain reaction
Number of subjects: 98
Study: 16129384

Group type: EXPERIMENTAL
Intervention: Memantine treatment
Number of subjects: 0
Study: 12162601

Group type: EXPERIMENTAL
Intervention: 12 h cyclical lighting (intensity of light: 78.4 +/‐ 24.7 lux)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Continuously dim environment (5.9 +/‐ 1.9 lux)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 12 h cyclical lighting
Number of subjects: 96

Group type: COMPARATOR
Intervention: Continuously dim environment
Number of subjects: 96
Study: 10782903

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 14-16 mg/kg/day
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 192
Study: 8903001

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (30 mg; i.m.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dipyrone (1.0 g; 2.5 g; i.v.)
Number of subjects: 12
Study: 1853794

Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional-dose antibiotic treatment
Number of subjects: 53
Study: 6191994

Group type: EXPERIMENTAL
Intervention: Naloxone (40 micrograms kg‐1 h‐1, i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 10
Study: 30590537

Group type: EXPERIMENTAL
Intervention: Ivermectin 300 mcg/kg/day
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ivermectin 600 mcg/kg/day
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 29793404

Group type: EXPERIMENTAL
Intervention: Immediate treatment for GDM
Number of subjects: 4000

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 4000
Study: 26871879

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 151

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 151
Study: 24725909

Group type: EXPERIMENTAL
Intervention: Balloon-expandable bare-metal stents (BMSs)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Covered balloon-expandable stents (CBE)
Number of subjects: 162
Study: 22433473

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (520 mg/day of elemental magnesium)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Magnesium citrate (295.8 mg/day of elemental magnesium)
Number of subjects: 41
Study: 20060161

Group type: EXPERIMENTAL
Intervention: 800 microg misoprostol
Number of subjects: 978

Group type: COMPARATOR
Intervention: 40 IU intravenous oxytocin
Number of subjects: 978
Study: 17606475

Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lorazepam (1.5 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16208149

Group type: EXPERIMENTAL
Intervention: Telmisartan (20, 40, or 80 mg)
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg)
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1039
Study: 12356955

Group type: EXPERIMENTAL
Intervention: Structured reports by standardised patients (SPs) who presented unannounced to the physicians' clinics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Abstraction of the medical records generated during these visits
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Structured reports by standardised patients (SPs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Abstraction of the medical records
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Individual physician subjects
Number of subjects: 20
Study: 10411366

Group type: EXPERIMENTAL
Intervention: Low-dose combination therapy (5 mg enalapril + 5 mg felodipine ER once daily)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Higher dose of monotherapy (10 mg enalapril once daily)
Number of subjects: 217
Study: 7480492

Group type: EXPERIMENTAL
Intervention: Experimental groups (n = 101)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: General psychiatric patients (n = 64)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: General adult normative population (n = 564)
Number of subjects: 729
Study: 1443507

Group type: EXPERIMENTAL
Intervention: 2 mg/kg ketamine racemate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg/kg S-(+)-Ketamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg/kg S-(+)-Ketamine after 0.1 mg/kg midazolam premedication
Number of subjects: 30

Group type: COMPARATOR
Intervention: ketamine racemate
Number of subjects: 30

Group type: COMPARATOR
Intervention: S-(+)-Ketamine
Number of subjects: 30
Study: 3550071

Group type: EXPERIMENTAL
Intervention: guanethidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 29758155

Group type: EXPERIMENTAL
Intervention: 67% NaHCO3 toothpaste
Number of subjects: 246

Group type: COMPARATOR
Intervention: 0% NaHCO3 toothpaste
Number of subjects: 246
Study: 26865074

Group type: EXPERIMENTAL
Intervention: Prenatal supplementation with folic acid, iron‐folic acid, and multiple micronutrients
Number of subjects: 834